Delving into the Latest Updates on Jiangsu Jibeier Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Other Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	7

Top 5 Target	Count

ATPase	1
Free radicals	1
Tubulin	1
Na/K-ATPase(Sodium/potassium-transporting ATPase)	1
DAT x NET x SERT	1

Primary purpose: To evaluate the safety and tolerability of JJH201601 liposomes for injection in patients with malignant solid tumors; Secondary purpose: To observe the pharmacokinetic characteristics of JJH201601 liposomes for injection in patients with malignant solid tumors and obtain preliminary pharmacokinetic parameters; To preliminarily observe the efficacy of JJH201601 liposomes for injection.

Start Date11 Aug 2023

Sponsor / Collaborator

Jiangsu Jibeier Pharmaceutical Co. Ltd.

NCT05780294 / Not yet recruitingPhase 3IIT

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-fluorouracil Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic Nasopharyngeal Carcinoma

Toxic and side effects during and after chemoradiotherapy for nasopharyngeal carcinoma seriously affect patients' treatment compliance and long-term quality of life. Active and effective prediction, prevention and management of toxic and side effects is an important element to improve the prognosis of patients. Leucogen has the ability to promote the growth and maturation of granulocytes in the bone marrow and the proliferation of leukocytes, and is widely used in radiation therapy and chemotherapy-induced leukopenia in malignant carcinomas. In addition, leucogen may have potential anticancer synergistic effects. Therefore, based on the application prospect of leucogen in preventing myelosuppression during chemotherapy for solid tumors, the study was designed to investigate the efficacy and safety of leucogen versus placebo on leukocyte and platelet whole-course management assisted by platinum plus low-dose long-term continuous intravenous infused 5-fluorouracil chemotherapy in the treatment of stage IV, recurrent or metastatic nasopharyngeal carcinoma.

Start Date01 Apr 2023

Sponsor / Collaborator

Sun Yat-Sen University

[+1]

100 Clinical Results associated with Jiangsu Jibeier Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangsu Jibeier Pharmaceutical Co. Ltd.

Login to view more data

6

Literatures (Medical) associated with Jiangsu Jibeier Pharmaceutical Co. Ltd.

Qilu Yaoshi

Isolation and purification of total flavonoids from Lysimachia christinae

Author: Gu, Rong ; Wei, Fu-rong ; Zhao, Lei

The optimal condition for purifying total flavonoids from Lysimachia christinae with macroporous resin was investigated.The gradient elution of ethanol was used and the content of total flavonoids in Lysimachia christinae was determined by UV spectrophotometry.The purity of total flavonoids can be up to 70.6% under the conditions that HPD400 type of macroporous resin was used as absorption agent, purified water was used to rinse and 50% ethanol 1.5 BV was used as elution agent.It was feasible to isolation and purification of total flavonoids from Lysimachia christinae with HPD400 resin.

Shandong Huagong

The pilot study on the inhibition of safflower polysaccharide to human gastric carcinoma cell line BGC-823

Author: Wu, Xiaofeng ; Shi, Mingjun ; Jiang, Ru

Objective: To observe the effect of safflower polysaccharide on the cell proliferation and apoptosis of human gastric carcinoma cell line of BGC-823.Methods: BGC-823 cells were processed with different concentrations of safflower polysaccharide during the same period.Cell viability was measured by MTT assay.Morphol. changes of the cells were observed under invert microscope after staining with Hoechst 33342.Results: Safflower polysaccharide could inhibit the growth of BGC-823 cell lines in dosage and time dependant manner.Cells exhibited apoptosis in morphol.Conclusion Safflower polysaccharide could inhibit the proliferation and induce the apoptosis of gastric cancer cell lines of BGC-823.

Shandong Huagong

Determination of the genotoxic impurity epichlorohydrin in atenolol by GC-MS

Author: Tong, Shengling ; Li, Haidao ; Jiang, Ru

Objective: To establish a gas chromatog.-mass spectrometry (GC-MS) method for the determination of epichlorohydrin in atenolol.Method: The samples were separated on an DB-624 UI (30 m×0.32 mm×1.8μm) capillary column.The column temperature was maintained at 60°C, and then gradiently raised to 220°C.The flow rate of carrier gas was 1.5 mL·min^-1.Selected ion monitoring (SIM) was adopted for mass spectrometry, and m/z was 49 and 62.Results: The assay linearity of epichlorohydrin was confirmed over the range of 0.0354∼0.7088μg·mL^-1 (r=0.9999).The average recovery of epichlorohydrin was 98% and the RSD was 1% (n=9).The limit of determination was 0.0177μg·mL^-1.Conclusion: The method is sensitive and specific, which is suitable for the determination of epichlorohydrin in atenolol.

100 Deals associated with Jiangsu Jibeier Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Jiangsu Jibeier Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Phase 2 Clinical

Phase 3 Clinical

1

3

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Rifandine	Leprosy More	Approved
Deslanoside ( Na/K-ATPase )	Arrhythmias, Cardiac More	Approved
Acetylcysteine ( Free radicals )	Bronchitis, Chronic More	Approved
JJH201501 ( DAT x NET x SERT )	Depressive Disorder More	Phase 3
JJH-201601 ( Tubulin )	Hepatocellular Carcinoma More	Phase 2 Clinical